T-Ray Science Announces Addition to Board of Directors and Expansion of Its Investor Relations Program

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 28, 2010) - T-Ray Science, Inc. (TSX VENTURE: THZ) (“T-Ray” or the “Company”), announced today that Mr. Joseph Biegel has been nominated to the T-Ray board of directors to stand for election at the Company’s Annual General Meeting on July 15, 2010. Mr. Biegel is currently the Vice President of Product Management and Marketing for the Medical Imaging Division of McKesson Provider Technologies. He joined McKesson in 2004 and is responsible for developing product strategy and plans for the growing family of diagnostic imaging IT solutions from the McKesson Imaging Group.

Mr. Biegel has been working in digital imaging for over 27 years, and in diagnostic imaging for 19 years. Prior to joining McKesson, he served as Vice President of Business Development for Agfa Healthcare. Before joining Agfa via the acquisition of Mitra Corporation, he had senior roles in diagnostic imaging product development and marketing at Hewlett-Packard’s Medical Products Group, Polaroid Medical Imaging Systems and the DuPont Merck Pharmaceutical Company. Mr. Biegel also was on the faculty of the Rochester Institute of Technology’s Center for Imaging Science where he taught courses in imaging and computing and was involved in contract research programs for NASA and other US Government organizations.

Along with Mr. Biegel, five current directors are nominated for re-election including Thomas Braun, T-Ray’s CEO, Ralph Braun, T-Ray’s CFO, Karen Boodram, President of Biomanna Medical Business Development Consulting, Chris Dennis, President of Comcare Health Services, Inc. and Dr. Jake Thiessen, the Hallman Director of the School of Pharmacy and the Director of the Health Sciences Campus at the University of Waterloo.

“Joe’s extensive medical imaging background is an ideal addition to our Board as our skin cancer detection program begins to accelerate,” commented Thomas Braun, T-Ray’s CEO.

Mr. Biegel holds a Bachelor’s and a Master’s degree in Imaging Science from the Rochester Institute of Technology (1975-1986). He is a technical reviewer for the British Columbia Innovation Council and is a member of the board of Imaging the World (imagingtheworld.org), a non-profit organization committed to providing sustainable imaging solutions to help reduce the inequality of the world’s disparate healthcare access.

“I am very pleased to be nominated to join T-Ray’s board at this time,” commented Mr. Biegel. “I believe there is a strong medical need and commercial opportunity for a non-invasive device to detect both melanoma and non-melanoma skin cancer, and look forward to working with the company as it continues to develop this optical biopsy technology.”

Today T-Ray also announced that it has engaged SectorSpeak Inc. (the “Consultant”) to assist its investor relations activities, namely to introduce the company to investors and analysts, organize investor road shows and generally assist in corporate communication. Pursuant to a consulting agreement to be effective as of July 1, 2010, T-Ray will retain the services of the Consultant for an initial period of one year. T-Ray has agreed to pay to the Consultant a monthly compensation of $5,000 and to grant the Consultant an option to purchase 150,000 common shares of the company at a price of $0.20 per share for a period of five years. The options shall vest over a period of 12 months pursuant to TSX Venture policy. T-Ray also continues to engage Caliber Capital Partners, Inc. for investor relations, and has amended the number of options issued to Caliber to 150,000 from 250,000. All of the other terms of T-Ray’s agreement with Caliber remain unchanged.

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company centered on the development and commercialization of an innovative skin cancer detection system for the early diagnosis and treatment of all significant forms of skin cancer. (Including: melanoma, basal cell carcinoma and squamous cell carcinoma).

The Company’s patented imaging and spectroscopy technologies are the foundation for the development of the company’s non-invasive, in vivo skin cancer detection and delineation system. This diagnostic tool will deliver significant clinical impact through improved patient outcomes, and will reduce healthcare costs by eliminating the need for most biopsies. The platform technology is extensible to other forms of cancer including lung and cervical cancers.

Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of THz based products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.